Which are the Emerging Companies of Drug Delivery Devices Industry in 2026?

Introduction of the Drug Delivery Devices Industry

The global drug delivery devices industry in 2026 is experiencing accelerated innovation, driven by the rising prevalence of chronic diseases, biologics expansion, patient-centric care models, and the rapid adoption of home-based treatment solutions. According to Cognitive Market Research, the drug delivery devices industry is transitioning from conventional syringe-based administration toward smart, connected, minimally invasive, and self-administered drug delivery platforms.

Pharmaceutical and biotechnology companies across North America, Europe, and Asia-Pacific are increasingly integrating advanced delivery technologies to enhance therapeutic efficacy, improve patient adherence, and reduce hospital dependency. The growth of biologics, biosimilars, cell and gene therapies, and mRNA-based treatments is creating strong demand for precision-controlled, wearable, implantable, and digitally monitored drug delivery systems.

Technological advancements such as connected autoinjectors, wearable infusion pumps, microneedle patches, inhalation-based biologic delivery, implantable pumps, and AI-enabled adherence tracking platforms are reshaping the competitive landscape. Emerging companies are leveraging miniaturization, microfluidics, smart sensors, and data analytics to develop next-generation delivery devices compatible with complex drug formulations.

However, challenges including regulatory approvals, sterility compliance, device-drug combination complexity, cybersecurity in connected devices, cost constraints, and supply chain dependencies remain critical considerations. These dynamics are encouraging strategic partnerships between medtech startups, pharmaceutical manufacturers, contract device manufacturers, and digital health platforms.

As healthcare systems increasingly emphasize personalized medicine and decentralized care, emerging drug delivery device companies in 2026 are combining precision engineering, digital integration, and patient-friendly design to define the next generation of therapeutic administration solutions.

Emerging Companies of the Drug Delivery Devices Industry

Insulet Corporation

Insulet develops tubeless insulin pump systems designed for automated insulin delivery.

• Key Innovation: Wearable, patch-based insulin pump with continuous glucose monitoring integration
• Focus Areas: Diabetes management, connected insulin therapy, home-based care

In 2026, Insulet continues to expand its smart insulin ecosystem, integrating real-time glucose data analytics and cloud-based monitoring to improve patient adherence and glycemic control.

Ypsomed

Ypsomed specializes in autoinjectors, pen injectors, and wearable delivery systems for biologics.

• Key Innovation: Modular autoinjector platforms for high-viscosity biologics
• Focus Areas: Rheumatology, oncology, biosimilars, large-volume subcutaneous delivery

The company’s customizable, patient-friendly injection platforms are widely adopted by pharmaceutical partners seeking reliable combination-device solutions.

West Pharmaceutical Services

West Pharmaceutical Services provides containment and delivery components for injectable drugs and biologics.

• Key Innovation: Integrated drug packaging and delivery systems
• Focus Areas: Prefilled syringes, cartridge systems, self-injection devices

In 2026, the company is strengthening its smart containment technologies to support high-value biologics and mRNA-based therapies requiring sterility and precision dosing.

Gerresheimer AG

Gerresheimer develops glass and polymer-based drug containment and delivery solutions.

• Key Innovation: Polymer-based prefillable syringe systems
• Focus Areas: Biologics delivery, injectable therapies, combination devices

Its innovations in lightweight, break-resistant polymer systems enhance patient safety and logistics efficiency in global pharmaceutical supply chains.

Enable Injections

Enable Injections focuses on wearable enabler platforms for high-volume subcutaneous biologic delivery.

• Key Innovation: On-body injector for large-volume biologics
• Focus Areas: Immunology, oncology, rare diseases

The company’s technology supports at-home administration of therapies that traditionally required hospital infusion, reducing healthcare burden and improving convenience.

Stevanato Group

Stevanato Group provides integrated containment, drug delivery, and diagnostic solutions.

• Key Innovation: Platform-based combination product development
• Focus Areas: Prefilled syringes, pen systems, cartridge-based injectors

In 2026, Stevanato is expanding its end-to-end device development services, supporting pharmaceutical firms from early-stage design through commercial-scale manufacturing.

MannKind Corporation

MannKind develops inhalation-based drug delivery systems using dry powder formulations.

• Key Innovation: Technosphere inhalation platform
• Focus Areas: Rapid-acting insulin, pulmonary drug delivery

The company’s inhaled therapeutic approach enhances rapid systemic absorption and offers needle-free administration options.

BD (Becton, Dickinson and Company)

BD is advancing smart injection devices and drug delivery platforms.

• Key Innovation: Connected autoinjectors and digital adherence tracking
• Focus Areas: Chronic disease management, biologics administration

In 2026, BD continues integrating digital health capabilities into injection systems, enabling remote patient monitoring and therapy optimization.

Elcam Drug Delivery Devices

Elcam develops precision plastic components and microfluidic solutions for drug delivery devices.

• Key Innovation: Microfluidic-based flow control systems
• Focus Areas: Infusion therapy, wearable pumps, combination devices

Its high-precision flow regulation systems enhance dosing accuracy in next-generation infusion platforms.

Micron Biomedical

Micron Biomedical is developing dissolvable microneedle patches for vaccine and biologic delivery.

• Key Innovation: Needle-free, thermostable microneedle patch
• Focus Areas: Vaccines, global immunization programs, biologics

The technology aims to simplify mass vaccination, reduce cold chain dependency, and improve patient compliance through painless self-administration.

Conclusion

The drug delivery devices industry in 2026 is defined by wearable injectors, connected autoinjectors, inhalation-based therapies, microneedle patches, smart containment systems, and large-volume subcutaneous biologic delivery platforms. Emerging companies such as Insulet Corporation, Ypsomed, West Pharmaceutical Services, Gerresheimer AG, Enable Injections, Stevanato Group, MannKind Corporation, BD, Elcam Drug Delivery Devices, and Micron Biomedical are reshaping therapeutic administration through innovation in precision, connectivity, and patient-centric design.

As per our research analyst, pharmaceutical companies, biotech innovators, and healthcare providers collaborating with these emerging device manufacturers can achieve improved patient adherence, enhanced drug stability, decentralized care expansion, and optimized therapeutic outcomes. With biologics growth, chronic disease prevalence, and digital health integration accelerating globally, these emerging drug delivery device companies are positioned to define the next generation of smart, scalable, and patient-friendly treatment solutions in 2026 and beyond.

Supriya Yadav  

Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sector…